{"filings":[{"id":95081,"accession_number":"0001104659-26-044093","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acurx raises ~$2.5M in registered direct offering plus up to $4.6M from warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 825,085 shares (or pre-funded warrants) at $3.03/share for ~$2.5M gross proceeds.","Concurrent private placement of 1,650,170 Series H warrants at $2.78/share, exercisable for 24 months.","Potential additional gross proceeds of ~$4.6M if short-term warrants fully exercised on cash basis.","Proceeds to be used for working capital and general corporate purposes.","H.C. Wainwright & Co. acted as exclusive placement agent; fees 6.0% of gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107893,"accession_number":"0001104659-26-025003","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Acurx launches ibezapolstat pilot trial in recurrent CDI; Phase 2 showed 96% cure, no recurrence","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO, Executive Chairman, CFO take 10% base salary cut; director cash retainers also reduced 10%, effective April 1, 2026.","Acurx opens open-label pilot trial for ibezapolstat in multiply-recurrent CDI (up to 20 patients); first enrollment expected Q4 2026.","Phase 2 data: ibezapolstat achieved 96% clinical cure (25/26) and 100% sustained cure with no recurrence at 1 month (25/25).","Beneficial gut microbiome preservation and bile acid data suggest potential for single-agent treatment and prevention of rCDI.","Company plans to seek FDA approval under LPAD pathway for rCDI treatment and prevention after Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140984,"accession_number":"0001104659-25-092166","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Acurx increases authorized common stock from 200 million to 250 million shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment at special meeting on September 16, 2025.","Authorized common stock increased from 200,000,000 to 250,000,000 shares.","Amendment filed with Delaware Secretary of State on September 22, 2025, effective immediately.","Shares may be used for future capital raising, acquisitions, or other corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140983,"accession_number":"0001104659-25-091733","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acurx shareholders approve warrant exercise and authorized share increase at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (warrant exercise for Nasdaq compliance): 8,816,581 for, 602,155 against, 9,823,429 broker non-votes.","Proposal 2 (authorized share increase 200M to 250M): 16,476,460 for, 2,526,119 against, 363,000 abstentions.","Proposal 3 (adjournment) approved: 16,538,163 for, 2,271,234 against, 556,182 abstentions.","Quorum: 19,365,579 shares (63.44%) of 30,524,540 outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140982,"accession_number":"0001104659-25-072529","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals announces 1-for-20 reverse stock split effective August 4, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-20; effective 4:01 p.m. ET on August 4, 2025.","Post-split trading begins August 5, 2025 under ticker ACXP; new CUSIP 00510M 203.","Outstanding shares reduced from ~30.8M to ~1.5M; authorized shares unchanged.","Fractional shares paid in cash based on August 1, 2025 closing price.","Split approved by stockholders at July 17, 2025 annual meeting; intended to regain Nasdaq minimum bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140981,"accession_number":"0001104659-25-068659","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acurx shareholders approve reverse split, equity plan increase, and director elections at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six proposals passed at July 17 meeting; 74.38% of shares represented.","Reverse stock split authorized at ratio 1:10 to 1:30; board to set timing and exact ratio.","2021 Equity Plan share reserve increased from 177,448 to 2,677,448 shares.","Directors Sailer and Harrison re-elected; auditor CohnReznick ratified; warrant exercise and ELOC approved for Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158750,"accession_number":"0001104659-25-060902","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acurx Pharma raises $2.67M via warrant exercise; issues new warrants for ~8.89M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered warrant inducement agreement; holder exercised ~4.45M existing warrants at reduced $0.60/share, gross proceeds $2.67M.","Net proceeds ~$2.3M after fees; used for working capital and general corporate purposes.","Issued new G-1 and G-2 warrants to purchase up to 8,890,870 shares at $0.425/share; G-1 exercisable immediately, G-2 upon shareholder approval.","H.C. Wainwright gets 7% fee and warrants to purchase 266,726 shares at $0.75/share.","Expected close June 20, 2025; 45-day stock issuance restriction and 90-day variable rate transaction restriction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158749,"accession_number":"0001104659-25-047566","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Q1 net loss narrows to $2.1M ($0.11/sh); cash $4.6M; EMA guidance for ibezapolstat Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.1M ($0.11 diluted EPS) vs $4.4M ($0.28) Q1 2024; R&D fell to $0.6M, G&A to $1.6M.","Cash $4.6M at March 31, 2025, up from $3.7M at year-end 2024 after two offerings raising ~$3.6M gross.","Closed $2.5M registered direct offering in Jan 2025 and $1.1M offering in Mar 2025; $12M Lincoln Park equity line closed in May.","Received positive EMA regulatory guidance for ibezapolstat Phase 3 program, aligned with FDA, confirming MAA pathway.","Japanese and Indian patent offices granted new DNA polymerase IIIC inhibitor patents expiring Dec 2039 for ACX-375C."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158748,"accession_number":"0001104659-25-046167","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals secures up to $12M equity line from Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lincoln Park committed to purchase up to $12M in common stock over 24 months.","Regular purchases up to 60k shares/day (90k if stock ≥$2, 120k if ≥$3).","Purchase price set at 97% of lowest of day's low or avg of three lowest closes in prior 10 days.","Company issued 899,258 commitment shares to Lincoln Park as consideration.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177151,"accession_number":"0001104659-25-029370","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.","Company has 45 days (until May 9, 2025) to submit a Compliance Plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","If plan rejected, common stock subject to delisting; company can appeal to Hearing Panel.","Company cautions no assurance that plan will be accepted or compliance regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177150,"accession_number":"0001104659-25-024731","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma reports FY 2024 net loss $14.1M; cash $3.7M; EMA guidance for Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $2.8M ($0.16/diluted share) vs $5.1M ($0.37) in Q4 2023; FY 2024 net loss $14.1M ($0.87) vs $14.6M ($1.15).","Cash at Dec 31, 2024: $3.7M, down from $7.5M; raised $6.6M via ATM in 2024 plus $3.6M in direct offerings in early 2025.","Positive EMA guidance for ibezapolstat Phase 3 program aligned with FDA; regulatory pathway for MAA after Phase 3 completion.","Japan patent granted for DNA pol IIIC inhibitors (expires 2039); advancing ACX-375C for MRSA/VRE/Anthrax.","Phase 2 data: 96% clinical cure, 100% sustained cure at 1 month; non-clinical studies show microbiome-restorative potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177149,"accession_number":"0001104659-25-021978","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals raises $1.1M in registered direct offering and private warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate gross proceeds of ~$1.1M from 2.15M common shares and 595K pre-funded warrants at $0.40/share.","Private placement includes Series F warrants for up to 8.235M shares at $0.40, exercisable upon stockholder approval.","H.C. Wainwright exclusive placement agent; 7% cash fee plus warrants for 164,700 shares at $0.50.","Net proceeds to be used for working capital and general corporate purposes.","Offering expected to close on or about March 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177148,"accession_number":"0001104659-25-017437","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.","Company has until August 25, 2025 to regain compliance by closing at $1.00 or higher for 10 consecutive business days.","If compliance not met, Company may seek a second 180-day period via a reverse stock split if other listing standards are met.","No immediate effect on listing; stock continues trading on Nasdaq Capital Market under symbol 'ACXP'.","Company intends to monitor bid price and consider available options but can provide no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177147,"accession_number":"0001104659-25-001586","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acurx Pharmaceuticals prices $2.5M registered direct offering of 2.46M shares at $1.015","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.5M from 2,463,058 shares at $1.015/share in registered direct offering.","Concurrent private placement of Series E warrants to buy up to 2,463,058 shares at $0.90, exercisable for 5 years.","Net proceeds to be used for working capital and general corporate purposes; closing expected Jan 7, 2025.","Placement agent H.C. Wainwright receives 7% cash fee and warrants for 147,783 shares at $1.2688.","Affiliate investors (including CEO and Executive Chairman) purchase 167,488 shares in the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193933,"accession_number":"0001104659-24-117214","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma Q3 net loss $2.8M; cash $5.8M; advancing ibezapolstat Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.8M ($0.17/diluted share) vs $3.1M ($0.24) in Q3 2023; nine-month net loss $11.3M.","Cash $5.8M at Sep 30, 2024, down from $7.5M at Dec 31, 2023; raised $1.6M gross via ATM.","Requested FDA CMC meeting to start Phase 3 for ibezapolstat; USPTO patent granted through 2042.","R&D expenses $1.2M (Q3) vs $1.3M prior year; G&A $1.6M vs $1.8M prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210261,"accession_number":"0001104659-24-087545","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Q2 net loss $4.1M, cash $6.4M; FDA confirms Phase 3 readiness for ibezapolstat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.1M ($0.26/diluted share) for Q2 2024 vs. $3.4M ($0.28) in Q2 2023.","Cash $6.4M at June 30, 2024, down from $7.5M at Dec 31, 2023; raised $0.3M via ATM in Q2.","R&D expenses $1.8M (Q2 2024) vs $1.7M (Q2 2023); G&A $2.3M vs $1.7M.","Completed End-of-Phase 2 FDA meeting; agreement on Phase 3 and NDA plan for ibezapolstat (IBZ) for C. difficile.","USPTO granted IBZ patent expiring June 2042 covering reduced recurrence and microbiome health."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228555,"accession_number":"0001104659-24-072270","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acurx Pharmaceuticals announces results of annual shareholder meeting; directors elected, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 67.29% of outstanding shares (10,648,350 of 15,823,102) was present at June 17, 2024 Annual Meeting.","Class III directors Robert J. DeLuccia, Joseph C. Scodari, James Donohue re-elected with broker non-votes of 4,836,213 each.","Ratification of CohnReznick LLP as independent auditor for FY2024 passed with 10,542,955 votes for, 69,261 against, 36,134 abstentions.","All director nominees received majority of votes cast excluding broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228554,"accession_number":"0001104659-24-061579","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.","Cash $8.9M at March 31, 2024; raised ~$4.4M gross via ATM sale of 1,121,793 shares in Q1.","Phase 2b ibezapolstat results: 94% eradication of fecal C. difficile at Day 3 vs 71% for vancomycin; preserved gut microbiome.","End of Phase 2 meeting with FDA in April 2024; agreement reached on Phase 3 program and NDA pathway.","EMA approved SME designation for Acurx, granting fee reductions and support for European marketing authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247217,"accession_number":"0001104659-24-035556","cik":1736243,"company_name":"Acurx Pharmaceuticals, Inc.","ticker":"ACXP","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).","Year-end cash $7.5M; subsequent ATM raised ~$4.5M.","Ibezapolstat Phase 2b: 96% clinical cure (25/26), 100% sustained cure at 30 days.","FDA End of Phase 2 meeting scheduled April 2024; Phase 3 plan to be discussed.","EMA granted SME designation; additional microbiome data positive vs vancomycin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8380588.492462312,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}